-NasdaqGM
| Prev Close: |
6.85 |
| Open: |
6.75 |
| Bid: |
6.22 x 1000 |
| Ask: |
8.50 x 500 |
| 1y Target Est: |
13.00 |
| Beta: |
N/A |
| Next Earnings Date: |
| Day's Range: |
6.30 - 6.86 |
| 52wk Range: |
3.09 - 17.02 |
| Volume: |
115, 447 |
| Avg Vol (3m): |
899, 502 |
| Market Cap: |
128.03M |
| P/E (ttm): |
| EPS (ttm): |
-1.48 |
| Div & Yield: |
N/A (N/A) |
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- FPMI Trades At An 80 Percent Discount to Fair Value with Major Catalyst LoomingCompany Spotlight(Wed, Jun 17)
- PVH rallies after hours on earnings beatat MarketWatch(Mon, Jun 1)
- 6 Key Cancer Winners From ASCO Presentationsat 24/7 Wall St.(Mon, Jun 1)
- Vascular Biogenics shares surge after news of positive trial of brain tumor treatmentat MarketWatch(Mon, Jun 1)
- VBL Therapeutics Reports Updated Interim Results From Phase 2 Clinical Trial of VB-111 in Recurrent Glioblastoma (rGBM)GlobeNewswire(Mon, Jun 1)
- VBL Therapeutics to Present Phase 1/2a Data From VB-111 in Recurrent Platinum-Resistant Mullerian Cancer at the 2015 American Society of Clinical Oncology (ASCO) Annual MeetingGlobeNewswire(Sat, May 30)
- Vascular Biogenics Shares Could Doubleat Barrons.com(Tue, May 26)
- VBL Therapeutics to Webcast Analyst and Investor Event at American Society of Clinical Oncology (ASCO) Annual Meeting on June 1, 2015GlobeNewswire(Tue, May 26)
- Vascular Biogenics (VBLT) Shares March Higher, Can It Continue? - Tale of the TapeZacks(Fri, May 22)
- Coverage initiated on VBL Therapeutics by ROTH CapitalBriefing.com(Fri, May 22)
- Today's Volatility Alerts: What To Expect Next?Accesswire(Fri, May 15)
- The 5 Winners and Losers From ASCO Presentationsat 24/7 Wall St.(Thu, May 14)
- VBL Therapeutics to Present Positive Phase 1/2 Data for VB-111 in Recurrent Platinum-Resistant Mullerian Cancer at ASCO Annual MeetingGlobeNewswire(Wed, May 13)
- Vascular Biogenics Ltd Earnings Call scheduled for 8:30 am ET todayCCBN(Tue, May 12)
- Vascular Biogenics reports 1Q lossAP(Tue, May 12)
The broker you select will become the default broker for Trade Now
Key Statistics
| Forward P/E (1 yr): |
| P/S (ttm): |
| Ex-Dividend Date: |
Analysts
| Annual EPS Est (Dec-15) : |
-0.78 |
| Quarterly EPS Est (Jun-15) : |
-0.17 |
| Mean Recommendation*: |
2.5 |
| PEG Ratio (5 yr expected): |
Interesting facts
-
Newgenics (also known as free-market eugenics, and liberal eugenics) is the belief that people should not have any genetic altercation to any significant degree. Newgenics is distinguishable in genetic enhancement and the idea of extropy. This is the concept of the anti-transhumanists, bio-conservatives, and human exceptionalists. Certain...
Source: finance.yahoo.com
